The weekly litigation news digest is live. Subscribe now

IP Verse

Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect - EP3368071

The patent EP3368071 was granted to Revance Therapeutics on Jan 26, 2022. The application was filed on Oct 28, 2016 under application number EP16860952A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3368071

REVANCE THERAPEUTICS
Application Number
EP16860952A
Filing Date
Oct 28, 2016
Status
Granted And Under Opposition
Dec 24, 2021
Publication Date
Jan 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
IPSEN BIOPHARMAOct 26, 2022MATHYS & SQUIREADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP1514556
DESCRIPTIONUS2010330123
DESCRIPTIONUS2011268765
DESCRIPTIONUS2013251770
DESCRIPTIONUS5877278
DESCRIPTIONUS6444209
INTERNATIONAL-SEARCH-REPORTUS2002028765
INTERNATIONAL-SEARCH-REPORTUS2011268765
OPPOSITIONEP1817051
OPPOSITIONEP2379104
OPPOSITIONUS2010330123
OPPOSITIONUS2011268765
OPPOSITIONUS2013251770
OPPOSITIONWO2010078242
OPPOSITIONWO2017075468
SEARCHUS2010330123
SEARCHUS2013251770

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents